Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;5(24):504.
doi: 10.21037/atm.2017.11.03.

Poly(GP) proteins: a potential pharmacodynamic marker in ALS and FTD

Mauricio Budini  1 , Alfredo Criollo  1   2
Affiliations
Editorial

Poly(GP) proteins: a potential pharmacodynamic marker in ALS and FTD

Mauricio Budini et al. Ann Transl Med. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare

Figures

Figure 1
Figure 1
Poly(GP) proteins as a potential pharmacodynamics marker in ALS and FTD. Gendron and colleagues showed that the testing of poly(GP) proteins in the CSF could be used to validate the efficacy of clinical trials for the treatment of c9ALS or c9ALS-FTD. ALS, amyotrophic lateral sclerosis; CSF, cerebrospinal fluid; RBPs, RNA-binding proteins; RAN, repeat-associated non-ATG; c9ALS, C9ORF72-associated ALS; FTD, frontotemporal dementia.
See this image and copyright information in PMC

Comment on

  • Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis.
    Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, O'Raw A, Cook C, Pregent L, Belzil V, van Blitterswijk M, Tabassian LJ, Lee CW, Yue M, Tong J, Song Y, Castanedes-Casey M, Rousseau L, Phillips V, Dickson DW, Rademakers R, Fryer JD, Rush BK, Pedraza O, Caputo AM, Desaro P, Palmucci C, Robertson A, Heckman MG, Diehl NN, Wiggs E, Tierney M, Braun L, Farren J, Lacomis D, Ladha S, Fournier CN, McCluskey LF, Elman LB, Toledo JB, McBride JD, Tiloca C, Morelli C, Poletti B, Solca F, Prelle A, Wuu J, Jockel-Balsarotti J, Rigo F, Ambrose C, Datta A, Yang W, Raitcheva D, Antognetti G, McCampbell A, Van Swieten JC, Miller BL, Boxer AL, Brown RH, Bowser R, Miller TM, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Traynor BJ, Disney MD, Benatar M, Silani V, Glass JD, Floeter MK, Rothstein JD, Boylan KB, Petrucelli L. Gendron TF, et al. Sci Transl Med. 2017 Mar 29;9(383):eaai7866. doi: 10.1126/scitranslmed.aai7866. Sci Transl Med. 2017. PMID: 28356511 Free PMC article.

References

    1. Cruts M, Gijselinck I, Van Langenhove T, et al. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci 2013;36:450-9. 10.1016/j.tins.2013.04.010 - DOI - PubMed
    1. Budini M, Buratti E, Morselli E, et al. Autophagy and Its Impact on Neurodegenerative Diseases: New Roles for TDP-43 and C9orf72. Front Mol Neurosci 2017;10:170. 10.3389/fnmol.2017.00170 - DOI - PMC - PubMed
    1. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245-56. 10.1016/j.neuron.2011.09.011 - DOI - PMC - PubMed
    1. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-68. 10.1016/j.neuron.2011.09.010 - DOI - PMC - PubMed
    1. van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 2013;12:978-88. 10.1016/S1474-4422(13)70210-2 - DOI - PMC - PubMed

LinkOut - more resources